Roche Holding AG's shares have undergone a tumultuous period, characterized by both slips and gains. Despite a
modest outlook for 2024 and concerns regarding
research setbacks, Roche also revealed a series of promising developments. The company is joining the race for obesity drugs with a
$2.7 billion Carmot deal, it acquired
U.S. rights to a bowel disease drug from Roivant for
$7.1 billion and parts of LumiraDx diagnostics platform for
$295 million. Furthermore, the company plans to
increase its dividend to CHF9.60. Notably, Roche inadvertently released
positive interim trial data on a lung cancer drug. Unfortunately, Roche's Q3 sales were down 3% because of
currency headwinds and a slump in COVID-19 sales. However, several analysts believe Roche's stock is undervalued. Individual investors hold a
55% stake in Roche, while institutions account of
36% of ownership. These groups have experienced frustrations as Roche's market cap has seen a reduction of CHF12b. Key operations such as purchasing the biologics site from
Lonza for $1.2 billion and chasing Novo's Ozempic, Wegovy with a
$3 billion deal provide hope in the company's ongoing growth strategy.
Roche Stocks News Analytics from Mon, 21 Aug 2023 07:00:00 GMT to Wed, 08 May 2024 10:54:42 GMT -
Innovation 5
- Information 8
- Rumor -6
